Endocrine Abstracts

JOINT2311

Acromegaly, characterized by excessive growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion, is associated with significant metabolic alterations. This study investigates the relationships between IGF-1, liver fibrosis FIB-4 and hepatic steatosis HSI indexes, and other endocrine and metabolic parameters in patients with acromegaly to better understand the systemic impact of the disease. This retrospective study included 150 consecutive patients, 96 met all criteria and complete data. FIB-4 (Age×AST/PLT×ALT^1/2) was used as a LF (liver fibrosis) predictor (<1.3 low risk [LR-LF], 1.3-2.67 intermediate risk [IR-LF], >2.67 high risk [HR-LF]). HSI [8×(ALT / AST) + BMI + 2 (if type 2 diabetes) + 2 (if female)] score of ≥ 36 predicted the presence of hepatic steatosis. Patients were grouped by age (<40, 40-60, >60 years). Spearman’s correlation assessed relationships between IGF-1, endocrine markers, onset age, and tumor size with FIB-4 and HSI. Group comparisons used ANOVA, Kruskal-Wallis, t-tests, or Mann-Whitney U tests as appropriate. The cohort consisted of 42% males and 58% females, with a mean age of 47.67 ± 14.62 years. The mean FIB-4 score was 1.03 (SD = 0.62), while the mean HSI score was 38.3 (SD = 7.01). Notably, 21 patients presented with a FIB-4 score greater than 1.3, and 60 had an HSI score exceeding 36. Age-related differences were observed, with IGF-1 (P = 0.0001) decreasing with age. Patients with type 2 diabetes had higher FIB-4 (1.18 ± 0.51 vs. 1.0 ± 0.64, P = 0.023). A significant negative correlation was identified between IGF-1 and FIB-4 (ρ = -0.36, P = 0.0004). Additionally, age correlated positively with HSI (ρ = 0.23, P = 0.0266). TSH and PRL negatively correlated with FIB-4 (ρ = -0.23, P = 0.0257 and ρ = -0.27, P = 0.0093, respectively. This study underscores the complex interplay between IGF-1, liver fibrosis markers, metabolic factors, and endocrine dysfunction in acromegaly. Higher IGF-1 levels may have a protective role against fibrosis progression, warranting further investigation into its clinical significance. Additionally, increasing age is associated with a higher risk of liver steatosis, highlighting the need for age-related monitoring of liver health in this population. Further studies are needed to assess IGF-1 impact on the liver.